New device, ‘old’ allergens. Allergic contact dermatitis caused by the Dexcom G7 glucose sensor

Abstract

AbstractBackgroundAllergic contact dermatitis (ACD) has been reported as an adverse effect from the use of several glucose sensors and insulin pumps from different manufacturers. Isobornyl acrylate (IBOA) has been identified as a major culprit sensitizer, but also other acrylates and (modified) colophonium have been reported as causes of ACD.ObjectivesTo report the two first cases diagnosed with ACD caused by the Dexcom G7 (DG7) glucose sensor.Patients and MethodsTwo children with suspected ACD from DG7 were patch tested with our medical device series with an addition of selected test preparations including two variants of modified colophonium – methyl hydrogenated rosinate (MHR) and glyceryl hydrogenated rosinate (GHR). Both patients were also tested with acetone extracts made from different parts of the DG7 sensor. The extracts were analysed by gas chromatography–mass spectrometry (GC–MS).ResultsBoth patients tested positive to IBOA, hydroabietyl alcohol and GHR. In addition, patient 1 had a positive reaction to MHR and patient 2 had a positive reaction to colophonium. The GC–MS analyses showed the presence of IBOA and colophonium‐related substances in the DG7 extracts.ConclusionsBoth patients were diagnosed with contact allergy to well‐known medical device‐related sensitizers. The presence of IBOA and (modified) colophonium in a newly introduced (on the Swedish market in 2023) glucose sensor is remarkable and indicates an inadequate toxicological assessment of the materials used in the sensor.